

1 Facilitating Serum Determination of Neuron Specific  
2 Enolase at Clinically Relevant Levels by Coupling On-line  
3 Molecularly Imprinted Solid-Phase Extraction to LC-  
4 MS/MS  
5

6 Nicholas McKitterick<sup>1</sup>, Tugrul Cem Bicak<sup>2</sup>, Peter A. G. Cormack<sup>2,\*</sup>, Léon Reubsaet<sup>1</sup> and Trine  
7 Grønhaug Halvorsen<sup>1,\*</sup>

8 <sup>1</sup> Section for Pharmaceutical Chemistry, Department of Pharmacy, University of Oslo, PO Box 1068  
9 Blindern, 0316 Oslo, Norway

10 <sup>2</sup> WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, Thomas Graham  
11 Building, 295 Cathedral Street, Glasgow G1 1XL, Scotland, UK

12 Corresponding authors:

13 Trine Grønhaug Halvorsen  
14 Section for Pharmaceutical Chemistry  
15 Department of Pharmacy  
16 University of Oslo  
17 P.O. Box 1068 Blindern  
18 0316 Oslo  
19 Norway  
20 E-mail: [trinegha@farmasi.uio.no](mailto:trinegha@farmasi.uio.no)  
21 Phone: +47 22855735  
22

23 Peter A. G. Cormack  
24 WestCHEM, Department of Pure and Applied Chemistry  
25 University of Strathclyde  
26 Thomas Graham Building  
27 295 Cathedral Street  
28 Glasgow G1 1XL  
29 Scotland  
30 UK  
31 E-mail: [peter.cormack@strath.ac.uk](mailto:peter.cormack@strath.ac.uk)  
32 Phone: +44-(0)141-548 4951

## 33 Abstract

34 The identification and quantification of biomarkers is essential for the diagnosis, treatment, and long-  
35 term monitoring of many human diseases. In the present work, macromolecular synthetic receptors  
36 with pre-determined affinity and selectivity for the signature peptide of a prognostically significant  
37 small cell lung cancer (SCLC) biomarker - neuron-specific enolase (NSE) – were prepared in a porous  
38 polymer microsphere format using a template-directed synthesis strategy performed under  
39 precipitation polymerization conditions. The polymer microspheres were packed into short trap  
40 columns and then exploited as molecularly selective sorbents in a fully automated, on-line molecularly  
41 imprinted solid-phase extraction (MISPE) protocol. The on-line MISPE protocol was optimised with  
42 respect to the composition of the loading mobile phase, the flow rate, and the extraction time. The  
43 molecularly imprinted polymers (MIPs) showed high affinity and useful selectivity for the peptide  
44 target - the hexapeptide ELPLYR - compared to non-imprinted control polymers. The MIPs were able  
45 to retain the biomarker on-column for extraction times of up to 20 minutes, and the on-line MISPE  
46 method enabled complete recovery of the biomarker over the linear range 10-100 ng mL<sup>-1</sup> when the  
47 biomarker was present in spiked buffer (R<sup>2</sup>=0.994). For extractions of ELPLYR from very complex  
48 biological matrices, the recoveries of ELPLYR from reversed-phase SPE (RP-SPE)-treated and untreated  
49 digested human serum were 100.8 ± 6.2% and 61.6 ± 1.9%, respectively. Extractions of ELPLYR from  
50 spiked untreated digested serum were linear in the range of 7.5-375 ng mL<sup>-1</sup> (R<sup>2</sup> = 0.99). The limit of  
51 detection (LOD) and limit of quantification (LOQ) for the biomarker in digested serum were estimated  
52 to be 1.8 ng mL<sup>-1</sup> and 6.0 ng mL<sup>-1</sup>, respectively, which is below the median reference level of NSE in  
53 humans (8.6 ng mL<sup>-1</sup>). This work sets in place the basis for a new diagnostic tool for SCLC that is  
54 sensitive, robust, automated, and antibody-free, and which works very well with complex human  
55 plasma samples.

56 *Keywords: on-line solid-phase extraction; molecularly imprinted polymers; liquid chromatography*  
57 *tandem mass spectrometry; low-abundant biomarkers; bottom-up proteomics*

## 58 1.0 Introduction

59 The identification and quantification of biomarkers of disease is essential for the diagnosis, treatment,  
60 and long-term monitoring of many common health conditions, including cancers. In this regard,  
61 several thousand putative biomarkers have been reported in the literature to date, and many new  
62 biomarkers are discovered every single year [1]. The classical methods used for biomarker analysis are  
63 normally antibody-based methods, such as enzyme-linked immunosorbent assays (ELISA) [2]. Whilst  
64 such antibody-based methods are usually sensitive and rapid, the raising of antibodies against  
65 biomarkers can be an expensive undertaking. Furthermore, the lead-in times for the development and  
66 production of new antibodies tend to be lengthy, which means that new antibody production  
67 struggles to keep pace with the rapid rate of discovery of new biomarkers. Furthermore, antibody-  
68 based assays can give rise to false positive and false negative results, although this particular limitation  
69 can be addressed to some extent by combining antibody clean-up with mass spectrometric  
70 determination. Nevertheless, the development and exploitation of antibody-free strategies in  
71 combination with mass spectrometry for targeted, rapid, sensitive, and accurate biomarker detection  
72 is very timely and of critical importance to human health.

73 Molecularly imprinted polymers (MIPs) are synthetic polymers with unique physicochemical  
74 properties that allow the targeted capture of neutral or charged molecules [3]. When used as antibody  
75 binding mimics, MIPs can bind strongly and selectively to a range of targets, from small molecule  
76 analytes through to macromolecules such as proteins, and even to whole cells [4]. Most commonly,  
77 the affinity of a MIP for its target is based upon non-covalent intermolecular interactions, such as  
78 hydrogen bonding, however the size and shape of the binding sites within the MIP play a role too [5].

79 MIPs have been shown to be robust, reusable materials [6], and, compared to the production of typical  
80 single-use antibodies, they can be produced efficiently using streamlined synthetic protocols. This is a  
81 major reason why MIPs are attracting interest as cost-effective alternatives to antibodies for the

82 analysis of some biomarkers. These recent developments are in addition to the use of MIPs in a range  
83 of other fields, including electrochemical sensors [7], drug delivery [8], protein crystallization [9],  
84 catalysis [10], and in separation science (*e.g.*, solid-phase extraction, SPE) [11]. MIPs have been used  
85 extensively for numerous applications in separation science for over 20 years [11]. Once optimised for  
86 loading and elution solvents, the versatility of MIPs allows for successful off-line and on-line SPE for a  
87 range of targets, including biomolecules [6]. On-line molecularly imprinted solid-phase extraction  
88 (MISPE) includes the field of imprinted materials incorporated into appropriate physical formats for  
89 packing into columns for on-line chromatographic analysis [12]. On-line MISPE in combination with  
90 liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers a robust automated platform  
91 for the analysis of biomarkers, and MISPE columns can be interfaced readily with both micro- and  
92 nano-LC systems [13-15]. A key advantage of moving to an automated, on-line mode of operation is  
93 reduced manual handling, which gives higher throughput and better reproducibility and repeatability  
94 than the analogous off-line methods.

95 A key development of MIPs is the extraction of biomolecules from biological fluids (*e.g.*, human  
96 serum). MIPs targeting many proteins and peptides have been developed. For proteins, the imprinting  
97 strategy involves either whole protein imprinting or imprinting of a smaller fraction of the protein such  
98 as the epitope or tryptic signature peptide. [16] Whole protein imprinting has been utilised for some  
99 high abundant proteins, while imprinting of a smaller fraction of the protein is used more commonly  
100 for low-abundant proteins [16]. Typically, the MIPs are exploited as microparticles and can be packed  
101 into SPE columns used in combination with LC-MS/MS for the selective extraction and quantification  
102 of low abundant protein and peptide biomarkers in complex matrices (*e.g.*, human serum) [17]. MIPs  
103 targeting the signature peptide of the small cell lung cancer (SCLC) biomarker progastrin-releasing  
104 peptide (ProGRP) were developed for use in on-line analysis [12] and used to extract the nonapeptide  
105 NLLGLIEAK from human serum, including from serum samples from patients diagnosed with SCLC.  
106 ProGRP is the most selective biomarker known for the detection and follow-up of SCLC (*i.e.*, most  
107 patients testing negative are not in a diseased state); however, in the clinic, ProGRP is usually

108 determined in parallel with a second SCLC biomarker, neuron-specific enolase (NSE). NSE is present in  
109 elevated levels in a range of cancers (*e.g.*, neuroblastoma, melanomas, and breast cancers) [18],  
110 however the combined determination of NSE and ProGRP improves the accuracy of the SCLC  
111 diagnosis. MIPs targeting NSE have been developed for use in electrochemical sensors [19], but not  
112 for off-line or on-line MISPE work. A method determining NSE from serum using LC-MS/MS and the  
113 bottom-up approach after immunocapture of the intact protein has been developed previously [18].  
114 In this work, the peptide ELPLYR was identified as a suitable signature peptide owing to its specificity  
115 combined with strong ionisation in electrospray ionisation. Therefore, ELPLYR presents an attractive  
116 template for MIPs for use in NSE determination as well.

117 The objective of the present work was to develop MIPs in an appropriate physical format for use as  
118 molecularly selective sorbents in on-line MISPE, for the capture of the signature peptide of NSE (the  
119 hexapeptide ELPLYR) from biofluids. To this end, precipitation polymerisation was used to deliver high  
120 quality, molecularly imprinted polymer microspheres that could be packed directly into trap columns.  
121 Subsequently, an on-line MISPE methodology was devised and optimised with a view to extracting  
122 ELPLYR from complex matrices, thereby validating the potential of MIPs for the analysis of NSE in  
123 human serum. Success will represent a significant advancement to the state-of-the-art and diagnostic  
124 power since it will now be possible to determine two diagnostically important SCLC biomarkers in  
125 human serum by MIP-based enrichment of signature peptides followed by LC-MS/MS.

## 126 2.0 MATERIALS AND METHODS

### 127 **2.1 CHEMICALS AND REAGENTS**

128 The peptide template (Z-ELPLY[Nle]F, 98.51%) was purchased from LifeTein (Somerset, NJ, USA).  
129 1,2,2,6,6-Pentamethylpiperidine (PMP, 99%), tetrabutylammonium hydroxide solution (TBA.OH, 1.0  
130 M in methanol, 25%), acetonitrile (ACN, 99%), divinylbenzene-80 (DVB-80, 80% DVB isomers and 20%

131 ethylvinylbenzene isomers), tetrahydrofuran (THF, 99%), methanol (MeOH, 99.8%), dimethyl sulfoxide  
132 (DMSO, 99%), hydrochloric acid (HCl, 37%), formic acid (FA, MS grade,  $\geq 98$ ), dithiothreitol ( $\geq 98\%$ , DTT)  
133 and iodoacetic acid ( $\geq 98\%$ , IAA) were purchased from Sigma Aldrich, St Louis, MO, USA. *N*-3,5-  
134 *bis*(Trifluoromethyl)-phenyl-*N'*-4-vinylphenylurea (TPVU, purity  $>95\%$ ) was kindly donated by Malmö  
135 University. 2,2'-Azobisisobutyronitrile (AIBN,  $\geq 98\%$ ) was purchased from BDH (Dubai, UAE).  
136 Acetonitrile LC-MS grade (MeCN, 99.9%), methanol LC-MS grade (MeOH, 99.9%), and acetic acid  
137 (AcOH, 100%) were purchased from Merck (Darmstadt, Germany). Ammonium bicarbonate (BioUltra,  
138  $\geq 99.5\%$ ) was purchased from Fluka (Milwaukee, WI, USA). Purified NSE ( $\gamma\gamma$ -dimer, Protein ID: P09104)  
139 was obtained from Scripps Laboratories (San Diego, CA, USA). Stable isotope labelled internal standard  
140 (IS) peptide ELPLY[R- $^{13}\text{C}_6^{15}\text{N}_2$ ] ( $>95\%$ ) was purchased from Innovagen (Lund, Sweden). Bovine serum  
141 albumin (BSA) and trypsin (TPCK-treated) from bovine pancreas (sequencing grade) were purchased  
142 from Sigma Aldrich. Water was filtered through a Merck Millipore Milli-Q Integral 3 water dispenser  
143 (resistivity: 18.2 M $\Omega$  cm). Human serum from consenting healthy individuals was obtained from Oslo  
144 University Hospital, Ullevål (Oslo, Norway). All serum samples were stored at  $-32\text{ }^\circ\text{C}$ .

## 145 **2.2 PREPARATION OF PROTEINS, STANDARD SOLUTIONS, AND**

### 146 **PURIFICATION OF REAGENTS**

147 NSE concentration was determined *via* UV absorbance (280 nm, A<sub>280</sub>) and the NSE stock diluted to  
148 the desired concentrations with 50 mM ammonium bicarbonate (ABC) and stored at  $-20\text{ }^\circ\text{C}$ .

149 A stock solution of the IS peptide was prepared in water at a concentration of 10 mM. The standards  
150 were diluted in 50 mM ABC for further use.

151 DVB-80 was passed through a short column of neutral alumina prior to use, and AIBN was  
152 recrystallized from acetone at low temperature.

## 153 **2.3 MIP SYNTHESSES**

154 See *Supplementary Information* for the MIP characterization data.

155 MIP 1 was prepared *via* precipitation polymerization using an adaptation of literature methods: To a  
156 borosilicate Kimax tube was added Z-ELPLY[Nle] (6.6 mg, 7.5  $\mu$ mol), PMP (1.8  $\mu$ L, 10  $\mu$ mol), DVB-80  
157 (1.01 g, 1.1 mL, 7.74 mmol), MeCN (20 mL) and THF (2.5 mL), and the mixture ultrasonicated for two  
158 minutes until a clear solution was obtained. TPVU (26.2 mg, 70  $\mu$ mol) and TBA.OH (70  $\mu$ L, 70  $\mu$ mol)  
159 were then added, and the mixture ultrasonicated for a further two minutes to dissolve all components.  
160 Then, AIBN (19.7 mg, 120  $\mu$ mol) was added and the mixture ultrasonicated for an additional five  
161 minutes and purged with oxygen-free nitrogen gas for 10 minutes at ambient temperature prior to  
162 sealing of the reaction vessel under nitrogen. The sealed tube was then placed into a pre-heated  
163 incubator (UVP hybridizer oven, Analytik Jena, Jena, Germany) at 60 °C, and left for 48 h at a rotation  
164 speed of  $\sim$  8 rpm, during which time a milky suspension of polymer microspheres formed. After cooling  
165 to room temperature, the polymer microspheres were isolated from the reaction medium by vacuum  
166 filtration on a 0.45  $\mu$ m nylon membrane filter and washed sequentially with MeCN (50 mL), MeOH/0.1  
167 M aq. HCl (90/10, v/v, 50 mL) and MeOH (50 mL). Finally, the product was dried overnight in a vacuum  
168 oven (60 °C, 50 mbar) to constant mass (yield: 49%). The corresponding non-imprinted polymer (NIP),  
169 NIP 1, was synthesized and isolated using the same procedure, except that the template and PMP  
170 were omitted from the synthetic protocol (Yield: 45%).

171 MIP 2 was prepared similarly to MIP 1, however higher amounts of TPVU (13.1 mg, 35  $\mu$ mol) and  
172 TBA.OH (35  $\mu$ L, 35  $\mu$ mol) were used and the yield of product was 51%. The corresponding NIP, NIP 2,  
173 was synthesized and isolated using the same procedure as MIP 2, except that the template and PMP  
174 were omitted from the synthetic protocol (Yield: 48%).

## 175 **2.4 COLUMN PACKING**

176 Each polymer (MIP 1 and MIP 2 and their corresponding NIPs) was wet packed into 1.5 x 5 mm PEEK  
177 cartridges. For this, each polymer (6 mg) was suspended in 380  $\mu$ L MeCN prior to ultrasonication for

178 five minutes. The polymers were vacuum-packed using heptane as the packing solvent at 100 bar.  
179 Each packed column was inspected under an optical microscope and asymmetry analysis performed  
180 to evaluate the packing quality (*see Supporting Information*).

## 181 **2.5 ON-LINE MISPE-LIQUID CHROMATOGRAPHY-TANDEM MASS** 182 **SPECTROMETRY**

183 The chromatographic system consisted of an ISO-3100 A loading pump, an LPG-3400 M pump with a  
184 degasser, a WPS-3000TRS autosampler, and an FLM3000 flow-manager (all Dionex, Sunnyvale, CA,  
185 USA). Extraction was performed by a MIP trap column. The chromatographic separation was carried  
186 out using an Aquasil C<sub>18</sub> analytical column (Thermo Scientific, 100 Å, 3 µm, 50 mm × 1 mm). The  
187 extraction was performed by injection of 2 µL of sample onto the MIP trap column. The MIP was then  
188 washed using an isocratic flow of 97:3 20 mM FA:MeCN at 20 µL min<sup>-1</sup> for 10 min (see set-up in Fig.  
189 1A). Following extraction, the system was switched to forward-flush the sample through the MIP  
190 column, the analytical column, and finally MS analysis. The microflow pump was directed to waste  
191 and kept at an isocratic flow of 50 µL min<sup>-1</sup> at 100% mobile phase A (20 mM FA and MeCN 95:5, v/v)  
192 during extraction (*i.e.*, for the first 10 min). After 10 min of loading, the chromatographic separation  
193 was performed using a 20 min linear-gradient from 0 to 85% mobile phase B (20 mM FA and MeCN  
194 5:95, v/v) after 3 min isocratic elution by mobile phase A. After the gradient was run, the column was  
195 washed for 3 min with 90% mobile phase B and re-equilibrated with mobile phase A for 20 min. The  
196 column temperature was set and kept constant at 25 °C.

197 A triple quadrupole mass spectrometer (TSQ Quantum Access, Thermo Scientific, Waltham, MA, USA)  
198 was used to determine the signature peptide and its corresponding IS by selected reaction monitoring  
199 (SRM) in positive mode. The following transitions pairs were monitored: for NSE- γ signature peptide  
200 ELPLYR, 395.7 → 274.7 and 395.7 → 548 with collision energy (CE) of 14 V; for the ELPLYR IS, 401.0 →  
201 279.7 and 401.0 → 558.3 with a CE of 14 V. The heated capillary temperature was set at 265 °C, and



202 the spray voltage was 4.0 kV. Auxiliary gas (N<sub>2</sub>): 10 arb., sheath gas (N<sub>2</sub>): 5 arb. TSQ data were  
203 processed by Xcalibur's QualBrowser (version 2.2 SP 1.48, Thermo Scientific), and MS responses based  
204 on the peak intensity, automatically processed by genesis peak detection algorithm, were used.  
205 Among them, only peaks with a signal-to-noise (S/N)-ratio above 10 and with retention time and ion  
206 ratios corresponding to those of reference samples at high concentration were considered.

## 207 **2.6 METHOD OPTIMISATION**

### 208 **Retention factor (k) calculation**

209 k was calculated using the following equation:

$$210 \quad k = (t_R - t_0)/t_0$$

211 Where  $t_R$  = Retention time,  $t_0$  = hold-up time

### 212 **2.6.1 Optimization of loading mobile phase composition and flow rate**

213 MIP 1 and MIP 2 (and their corresponding NIPs) were coupled directly to the MS (see Fig. 1B) and 2  $\mu$ L  
214 of ELPLYR IS was injected directly onto the MIP/NIP columns. This LC system consisted of the ISO-  
215 3100 A loading pump, the WPS-3000TRS autosampler, and the FLM3000 flow-manager. The loading  
216 mobile phases consisted of three different ratios of 20 mM FA and MeCN (100:0, 95:5, and 90:10 v/v).  
217 Three different flow rates were used: 20, 30, and 40  $\mu$ L min<sup>-1</sup>.

### 218 **2.6.2 Fine-tuning of the loading mobile phase composition**

219 The loading mobile phase was optimized further using MIP 1 and NIP 1. As above, 2  $\mu$ L of ELPLYR IS  
220 was injected directly onto the columns. The loading mobile phase consisted of 100:0, 99:1, 98:2, 97:3,  
221 96:4 and 95:5 v/v 20 mM FA and MeCN. The flow rate was set to 20  $\mu$ L min<sup>-1</sup>.

### 222 **2.6.3 Optimisation of loading time (extraction time)**

223 The loading time was evaluated using MIP 1 as a trap column (Fig. 1B). ELPLYR IS (2  $\mu\text{L}$ ) was injected  
224 onto MIP 1 using the loading mobile phase consisting of 97:3 20 mM FA:MeCN at 20  $\mu\text{L min}^{-1}$ . The  
225 following loading (extraction) times were evaluated: 5, 7.5, 10, 12.5 and 20 min (n=3). Digested BSA  
226 peptides (50 nM, 2  $\mu\text{L}$ ) were analysed at 5, 10, and 20 min to evaluate the selectivity and optimal  
227 extraction time for sample clean-up. (For BSA MS transitions see *Supporting Information Table S1*)

#### 228 **2.6.4 Imprinting factor (IF) calculation**

229 IFs were calculated for each set of conditions using the k values for each MIP and its respective NIP  
230 using the following equation:

$$231 \quad IF = k(MIP)/k(NIP)$$

## 232 **2.7 METHOD EVALUATION**

### 233 **2.7.1 Protein digestion**

234 NSE- $\gamma$  standard solutions were diluted by ABC to a volume and concentration of 470  $\mu\text{L}$  and 53.2  $\mu\text{g}$   
235  $\text{mL}^{-1}$ , respectively. 10  $\mu\text{L}$  of 2.5 mM DTT (freshly prepared in ABC buffer) was added to the protein  
236 mixture and incubated at 60  $^{\circ}\text{C}$  (800 rpm) for 20 min. Afterward, the solution was cooled, and 10  $\mu\text{L}$   
237 of 10 mM IAA (freshly prepared in ABC buffer) was added. Incubation was carried out for 15 min at  
238 room temperature (800 rpm) in the dark. Digestion was initiated by the addition of trypsin (10  $\mu\text{L}$ , 125  
239  $\mu\text{g mL}^{-1}$  in 50 mM ABC) for an enzyme to substrate ratio of 1:20 (w/w) overnight at 37  $^{\circ}\text{C}$ . The resulting  
240 digest had a final concentration and volume of 50  $\mu\text{g mL}^{-1}$  and 500  $\mu\text{L}$ , respectively. The digest was  
241 divided into 10  $\mu\text{L}$  aliquots and stored at -32  $^{\circ}\text{C}$  until further use.

242 BSA standards were diluted with ABC (50 mM) to a final volume and concentration of 500  $\mu\text{L}$  and 50  
243  $\mu\text{g mL}^{-1}$ , respectively. 2.5  $\mu\text{L}$  of 50 mM DTT (freshly prepared in ABC buffer) was added to the protein  
244 mixture and incubated at 60  $^{\circ}\text{C}$  (800 rpm) for 20 min. Afterward, the solution was cooled, and 2.5  $\mu\text{L}$   
245 of 200 mM IAA (freshly prepared in ABC buffer) was added. Incubation was carried out for 15 min at

246 room temperature (800 rpm) in the dark. Digestion was then accomplished by adding trypsin at an  
247 enzyme to substrate ratio of 1:20 (w/w) overnight at 37 °C.

### 248 **2.7.2 NSE digest extractions**

249 The on-line MISPE method was evaluated by determining the recovery and linearity of an NSE digest.  
250 For recovery determination, NSE digest 100 ng mL<sup>-1</sup> (10 µL) was diluted to a final concentration of 10  
251 ng mL<sup>-1</sup> by 50 mM ABC containing 25 nM of digested BSA (90 µL) (n=3). For linearity determination,  
252 NSE digest (50 µg mL<sup>-1</sup>) was diluted to 10, 25, 50 and 100 ng mL<sup>-1</sup> (n=3) with 50 mM ABC containing  
253 100 nM digested BSA. The samples were injected (2 µL) onto MIP 1. The loading/extraction time was  
254 set to 10 min followed by gradient elution and analysis. To determine the extraction recovery, a  
255 control sample of 25 ng mL<sup>-1</sup> of NSE digest in 50 mM ABC was analysed without the presence of the  
256 MIP column to determine the signal w/o MIP (=100% recovery).

## 257 **2.8 COMPLEX MATRIX EXTRACTIONS**

### 258 **2.8.1 RP-SPE treatment of digested serum**

259 For analyses of more complex matrices, RP-SPE treated serum was selected as a sample with  
260 complexity intermediate between a simple NSE digest and untreated digested serum. An in-house RP-  
261 SPE treatment was performed as described previously [20]. Briefly, SPE tips were made in-house by  
262 punching out six discs of C8 3M Empore material (Teknolab AS, Kolbotn, Norway) and packing them  
263 into the lower part of a 300 µL bevel point pipette tip (VWR, Hanover, Germany) using a metal wire.  
264 The SPE material was activated with 100 µL of MeCN followed by 100 µL of 20 mM FA. Digested serum  
265 (50 µL) was transferred to the SPE tip. The tips were then washed with 100 µL of 20 mM FA before  
266 being eluted with 100 µL of MeCN/0.01% (v/v) TFA in the ratio 80:20. The eluent was evaporated to  
267 dryness at 60 °C under N<sub>2</sub> gas and reconstituted in 50 µL of 50 mM ABC.

### 268 **2.8.2 Human serum digestion**

269 Human serum was defrosted at 4 °C for 1 h. 200 µL of serum was diluted 1:1 with 100 mM ABC before  
270 the addition of 200 mM freshly prepared DTT (10 µL) in 50 mM ABC. The samples were incubated at  
271 60 °C for 1 h. and allowed to cool to room temperature before the addition of 10 µL of freshly prepared  
272 500 mM IAA in 50 mM ABC. The samples were incubated at room temperature (800 rpm) for 30 min  
273 in the dark prior to the addition of 70 µL of 10 mg mL<sup>-1</sup> trypsin freshly prepared in 50 mM ABC. The  
274 samples were digested overnight at 37 °C. Digested serum was frozen at -20 °C until required.

### 275 **2.8.3 Determination of recoveries in complex matrices**

276 Recoveries were evaluated in two complex matrices: NSE digest spiked into RP-SPE-treated digested  
277 human serum, and NSE digest spiked into digested serum. NSE digest (1875 ng mL<sup>-1</sup>; 10 µL) was spiked  
278 into 90 µL of RP-SPE-treated digested human serum or 1:1 diluted (in 50 mM ABC) digested human  
279 serum for a final NSE digest concentration of 375 ng mL<sup>-1</sup>. To determine the extraction recoveries, a  
280 control sample of 187.5 ng mL<sup>-1</sup> of NSE digest in 50 mM ABC was analysed without the presence of the  
281 MIP column to determine the signal w/o MIP (=100% recovery). Following this, each sample type (n=3)  
282 was injected onto the standard trap system and the relative signal intensity used to determine  
283 recoveries.

### 284 **2.8.4 Linearity, LOD and LOQ**

285 Digested serum samples (40 µL) were spiked with 5 µL of various concentrations of digested NSE and  
286 5 µL of ELPLYR IS to final concentrations of 7.5, 37.5, 75, 187.5, and 375 ng mL<sup>-1</sup> NSE and 2 ng mL<sup>-1</sup> of  
287 IS and weighted 1/x (n=3). The signal (S) of ELPLYR in the 7.5 ng/mL digested NSE in digested serum  
288 sample and the noise (N) in the digested blank serum sample were used to calculate the LOQ (S/N =  
289 10) and LOD (S/N = 3). The respective chromatograms are seen in Fig. S2.

## 290 **3.0 Results and Discussion**

### 291 **3.1 TEMPLATE DESIGN AND OPTIMIZATION OF MIP SYNTHESSES**

292 Precipitation polymerization (PP) is a surfactant/stabilizer-free method for synthesising high quality  
293 crosslinked polymer microspheres in good yields, with good control over microsphere diameter,  
294 chemical functionality, and porous morphology. Typically, monomers are polymerised under dilute  
295 conditions in near-theta solvents, and products with narrow particle size distributions and bead  
296 diameters in the low-micron size range are formed. Such products are very well-suited for high-  
297 performance chemical separation work, including as stationary phases in LC and as SPE sorbents. It  
298 was for this reason that PP was the polymer synthesis method of choice in the present work.

299 ELPLYR (*i.e.*, H-Glu-Leu-Pro-Leu-Tyr-Arg-OH) (Fig. 2A) was selected as the signature peptide for NSE  
300 based on a previous study which used this peptide as a surrogate for the determination of NSE from  
301 serum [18]. The peptide is specific for the  $\gamma$ -subunit of NSE which is present in both the heterodimeric  
302 ( $\alpha\gamma$ ) and homodimeric ( $\gamma\gamma$ ) form of NSE. The sequence ELPLYR (AA 127-132) is found on the outside of  
303 each the  $\gamma$ -monomer. Therefore, it may be more readily accessible to trypsin during digestion,  
304 improving cleavage efficiency, and generating a more intense signal during analysis. ELPLYR was not  
305 used as the template in the production of MIPs because bleeding/leaching of residual template from  
306 ELPLYR imprinted polymers would be expected to occur during exploitation of such MIPs for ELPLYR  
307 capture from tryptic digests, and bleeding/leaching of the template, where the template is structurally  
308 identical to the analyte, is unacceptable in ultra-trace analyses where the analyte concentration is very  
309 low (N.B. the reference levels of NSE in humans is 8.6 ng/mL). A template analogue approach must,  
310 therefore, be used. In the design of a suitable template analogue for ELPLYR, some of the key  
311 considerations for the template analogue were: 1) Structural similarity to ELPLYR; 2) Cost and  
312 availability; 3) Solubility (in the porogens preferred for MIP production by PP); 4) Conformation and  
313 conformational rigidity; 5) Stability; 6) Functional groups available for templating. In a tryptic digest,  
314 any peptides present which contain C-terminal arginine are expected to bind appreciably and in a non-  
315 selective manner to a MIP prepared using a peptide template where the C-terminus of the template  
316 is arginine and this residue was targeted *via* a non-covalent molecular imprinting protocol. Thus it was

317 decided to mutate the C-terminal arginine and build selectivity into the MIPs through amino acid  
318 residues other than the C-terminal arginine.

319 Based on the above considerations, the peptide used as a template analogue for the NSE signature  
320 peptide was Z-ELPLYR, where Z = Cbz = Carboxybenzyl (a protecting group for the peptide N-terminus),  
321 and Nle = norleucine (Fig. 2B). Points to note: 1) The introduction of the Z group, and the change of  
322 Arg to Nle, is expected to increase the solubility of the template in the porogens preferred for non-  
323 covalent molecular imprinting and PP; 2) The ionisable groups in the template analogue are all  
324 Brønsted acidic (the Brønsted basic groups present in H-ELPLYR-OH have been either protected or  
325 replaced); 3) The Glu side-chain and the C-terminal carboxylic acid are useful functional group handles  
326 for templating. Urea-based monomers for oxyanion binding are obvious functional monomer (FM)  
327 candidates; 4) The Tyr side-chain is also a potentially useful functional group handle for templating.

328 Establishing an appropriate ratio of FM to crosslinker is an important part of MIP design for SPE  
329 applications. If too little crosslinker is used then the polymers may not be porous in the wet state and  
330 access to binding sites may be impeded or prevented. On the other hand, whilst higher crosslinker  
331 levels are more likely to yield permanently porous materials, this may be at the expense of lower  
332 nominal binding capacity. Appropriate ratios of FM to crosslinker are normally arrived at through a  
333 process of trial-and-error. Given this background, the approach was to increase the relative amount  
334 of FM in the polymer network in a stepwise fashion in order to identify the best performing MIP,  
335 however when the FM content in the monomer feed was at a FM to crosslinker mol ratio of 1:50, the  
336 polymer particles formed through polymerisation started to aggregate and high quality particles could  
337 no longer be obtained (probably due to the less effective self-stabilisation of DVB particles bearing  
338 urea moieties derived from the FM). Therefore, we decided to synthesise and evaluate two different  
339 sets of MIPs (and their corresponding NIPs) where the ratios of FM to crosslinker in the monomer feed  
340 were around 1:200 and 1:100.

## 341 **3.2 METHOD OPTIMISATION**

### 342 **3.2.1 Initial testing of MIP/NIP pairs #1 and #2**

343 The initial round of testing of the MIP columns focused on optimising the composition of the loading  
344 mobile phase and the flow rate. For this, each column was coupled directly to the MS using a single  
345 pump (Fig. 1A), and ELPLYR IS (5 nM) in 50 mM ABC injected (2  $\mu$ L) onto each column (n=3). For each  
346 column, the k values of ELPLYR IS were determined under a range of conditions (mobile phases of  
347 different elution strength were used, and the flow rates were varied) to establish the chromatographic  
348 conditions under which the MIP could bind the target strongly and selectively. To establish binding  
349 selectivity imparted into the MIPs through templating, retention factors were measured in parallel for  
350 non-imprinted control polymers, and then an imprinting factor (IF) calculated for each set of  
351 conditions. The initial optimization of the composition of the loading mobile phase was performed  
352 using three different ratios of 20 mM FA and MeCN (v/v) since mixtures of 20 mM FA and MeCN were  
353 shown to be effective mobile phases in earlier on-line MISPE work targeting tryptic peptides [12].  
354 Similarly, the flow rates investigated (20, 30, and 40  $\mu$ L min<sup>-1</sup>) were based on earlier studies, with faster  
355 flow rates being preferred provided that shorter analysis times are not at the expense of analyte  
356 recovery.

357 The first mobile phase evaluated was 100% 20 mM FA (data not shown). It was found that there was  
358 no observable MS signal at any flow rate on either of the MIPs or NIPs, even after one hour of isocratic  
359 flow. This showed that both the MIPs and the NIPs retained the peptide strongly (no selectivity), which  
360 is unsurprising since non-selective binding is expected to dominate for divinylbenzene-based polymers  
361 when the mobile phase is fully aqueous. However, the peptide could be eluted off the polymers in the  
362 subsequent washing step, so the peptide is not bound irreversibly.

363 Subsequently, mixtures of 20 mM FA and MeCN (at ratios 95:5 and 90:10 (v/v)) were evaluated as the  
364 loading mobile phase. The k values are high right across the board, and range from 14.4 to 21.7, which

365 shows high affinity of the polymers for the target. When comparing the two MIPs (MIP 1 and MIP 2),  
366 MIP 1 has a consistently higher affinity for the target, and the difference between the polymers is  
367 greatest for the mobile phase with the highest organic content (90:10 20 mM FA:MeCN (v/v)). It was  
368 also found that the k values were influenced very little by the flow rate, which suggested that the  
369 contact time between polymers and peptide was sufficiently long for all flow rates investigated. The  
370 highest k value was obtained for MIP 1 at a flow rate of 20  $\mu\text{L min}^{-1}$  when using 95:5 20 mM FA:MeCN  
371 (v/v) as the mobile phase ( $21.7 \pm 1.3$ ). Under the same mobile phase and flow rate conditions, the  
372 corresponding NIP 1 had a k value of  $19.8 \pm 0.3$ , which gives an imprinting factor of 1.1. Whilst this is a  
373 modest imprinting factor, the affinity of MIP 1 for the target is high, and high levels of non-specific  
374 binding to the non-imprinted sorbents arise due to a combination of hydrophobic effects and  
375 hydrogen bonding interactions between carboxylate groups in the target and the pendent urea  
376 moieties that are distributed randomly throughout the polymers.

377 For MIP 2 and NIP 2, the k values were also found to be highest when using 95:5 20 mM FA:MeCN  
378 (v/v) as the loading mobile phase at a flow rate of 20  $\mu\text{L min}^{-1}$  ( $20.1 \pm 0.7$  and  $19.40 \pm 0.3$ , respectively),  
379 however, the IF value was lower (IF=1.04.). Thus, whilst affinity remains high there is a fall in  
380 selectivity. When the amount of MeCN in the mobile phase was increased from 5% to 10% (*i.e.*, to  
381 90:10 20 mM FA:MeCN v/v) the k values decreased somewhat for all MIPs and NIPs which is consistent  
382 with a disruption of non-selective binding *via* hydrophobic effects. For all the mobile phases and flow  
383 rates evaluated, there is no significant difference (two-sided T-test,  $P \geq 0.05$ ) in k values between any  
384 MIP and the corresponding NIP except for MIP 1 and NIP 1 at a flow rate of 40  $\mu\text{L min}^{-1}$  when using  
385 90:10 20 mM FA:MeCN (v/v) as the mobile phase ( $P=0.0009$ ). However, with this mobile phase, the k  
386 values for MIP 1 ( $16.5 \pm 0.3$ ) is up to 25% lower than that obtained when using the 95:5 20 mM  
387 FA:MeCN (v/v) mobile phase, and higher retention factors are normally preferable when working with  
388 complex samples where there will be more competition for binding sites.



389 In this initial round of testing, MIP 1 turned out to be the most promising polymer; it had a high affinity  
390 for the target together with a degree of selectivity. To improve the selectivity it was decided to fine-  
391 tune the mobile phase composition in the range 100:0 to 95:5 20 mM FA:MeCN (v/v). For this part of  
392 the MISPE optimisation, the flow rate was fixed at 20  $\mu\text{L min}^{-1}$ .

### 393 **3.2.2 Fine-tuning of the loading of MIP 1**

394 The fine-tuning of the mobile phase composition for the loading of MIP 1 was performed using mobile  
395 phases containing 95:5, 96:4, 97:3, 98:2, and 99:1 ratios of 20 mM FA:MeCN (v/v). Similarly to the  
396 results obtained when the mobile phase was 100% 20 mM FA (*i.e.*, under fully aqueous loading  
397 conditions), ELPLYR was not eluted within one hour when using 98:2 and 99:1 20 mM FA:MeCN (v/v)  
398 as the mobile phase (data not shown). However, for the three other mobile phase compositions  
399 investigated, there was a clear trend of increasing  $k$  values with decreasing MeCN. At 95:5, 96:4 and  
400 97:3 20 mM FA:MeCN (v/v), the  $k$  values recorded for MIP 1 increased steadily from  $19.5 \pm 0.1$  to  
401  $20.3 \pm 0.4$  to  $23.8 \pm 0.6$ , respectively (Fig. 3). NIP 1 showed a similar, but weaker, trend, with  $k$  values of  
402  $18.6 \pm 0.1$ ,  $19.1 \pm 0.3$ , and  $20.6 \pm 0.4$ , respectively. For all three of these mobile phases a significant  
403 difference between the MIP 1 and NIP 1  $k$  values was seen ( $P = 0.014-0.0005$ ). When loading with 97:3  
404 20 mM FA:MeCN (v/v), the highest  $k$  value on MIP 1 was obtained (23.8), giving an IF of 1.2. This is the  
405 highest IF obtained across all the conditions tested, and is slightly higher than the IF reported for  
406 earlier work concerning on-line-MISPE of tryptic peptides [12]. Accordingly, for the further  
407 optimisation work the mobile phase was fixed as 97:3 20 mM FA:MeCN (v/v), since strong affinity and  
408 useful selectivity were apparent under these conditions.

### 409 **3.2.3 Loading time (extraction time)**

410 The loading (extraction) time during on-line analysis is critical for ensuring maximal retention of the  
411 analyte of interest while simultaneously reducing the sample complexity as much as possible before  
412 analysis. This process ensures maximum sensitivity due to reduced matrix effects in the MS. A  
413 pragmatic balance must be struck between the duration of the extraction step, the recovery of the

414 target analyte, and the overall analysis time. To evaluate the loading (extraction) time, MIP 1 was used  
415 as a trap column and coupled to a triple quadrupole MS, as described in the Experimental (Fig 1A).

416 The recovery of ELPLYR when using a 5 min loading time was  $95.3 \pm 1.2\%$  (Table 1). The recovery  
417 increased to 100 % when loading for 7.5 min or longer. Thus MIP 1 can retain ELPLYR exceptionally  
418 well (there was no loss of peptide after 20 min, which equates to approximately 40 column volumes).  
419 However, to investigate in more detail the selectivity of the MIP for ELPLYR over other peptides,  
420 digested BSA was loaded onto the MIP.

421 The recovery of seven tryptic BSA peptides was determined using three different loading times (5, 10,  
422 and 20 min; Table 2). With a loading time of 5 min, the recoveries ranged from 9.5-107.5%, with an  
423 average recovery of  $66.5 \pm 12.4\%$ . When the loading time was doubled to 10 min, the average recovery  
424 was  $59.3 \pm 6.3\%$ . Increasing the loading time yet further to 20 min resulted in an average recovery of  
425  $55.0 \pm 5.4\%$ . An average recovery of 55-67 % for the seven tryptic BSA peptides, compared to essentially  
426 quantitative recovery of the target, implies moderate selectivity for ELPLYR, however only one peptide  
427 was retained as strongly as ELPLYR, LGEYGFQNALIVR, and this is most likely due to its isoelectric point  
428 ( $pI = 6.1$ ) being comparable to ELPLYR (6.0). Since there were no significant differences in non-specific  
429 binding as a function of extraction time, 10 min was selected as the optimum extraction time since  
430 the recovery of ELPLYR was 100% even after washing with over 20 column volumes of mobile phase.

### 431 **3.3 INITIAL EVALUATION OF ANALYTICAL PERFORMANCE**

432 The initial evaluation of the method involved determining the recovery and linearity to establish the  
433 binding capacity of the MIP in simple matrices. This gives an insight into the potential downstream  
434 compatibility of the MIP with extractions of complex matrices. The extraction recovery of ELPLYR was  
435 determined to  $100.4 \pm 5.0\%$  in a sample of digested NSE in 50 mM ABC containing digested BSA (10  
436 times molar amount). Linearity was determined by injecting digested NSE in the range 10-100 ng mL<sup>-1</sup>  
437 <sup>1</sup> in 50 mM ABC containing a 100 nM digested BSA (n=3) onto the MIP column. Linear regression was

438 obtained by plotting the intensity of ELPLYR vs. the added concentration. The correlation value  
439 ( $R^2=0.99$ ) was within acceptable limits and is higher than for previously reported correlation columns  
440 [12].

### 441 **3.4 EXTRACTIONS FROM COMPLEX MATRICES**

442 Extractions from matrices of increasing complexity were evaluated to determine the compatibility of  
443 the on-line MISPE method with real biological samples and to verify the need to use a MIP for  
444 extraction when analysing complex samples. The latter was investigated as the MIP and NIP had shown  
445 similar retention factors of ELPLYR in extractions from simple matrices. Digested NSE was spiked into  
446 digested human serum pre-treated by off-line RP-SPE and also into untreated digested human serum;  
447 the recovery of ELPLYR was then determined for the two sample types (Fig. 4) using the MIP as a trap  
448 column; the latter sample was also analysed using the NIP as a trap column. When using the MIP as a  
449 trap column, the extraction recovery from RP-SPE treated serum was  $100.8\pm 6.2\%$ . Therefore, the  
450 extraction efficiency was comparable to those in a simple matrix. MIP extractions from the most  
451 complex matrix (digested serum), on the other hand, showed a lower but still acceptable recovery of  
452 ELPLYR ( $61.6\pm 1.9\%$ ). In comparison, when the NIP was used to extract digested NSE from serum, the  
453 recovery dropped to  $25.2\pm 1.7\%$ , demonstrating the effect of the imprinting in extraction from complex  
454 matrices.

455 The high recovery of ELPLYR from RP-SPE treated serum demonstrates that the MIP can enrich low  
456 abundant ELPLYR even when it is in the presence of high numbers of non-specific peptides. The  
457 recovery of ELPLYR from untreated, 1:1 diluted serum is lower than for the less complex matrices. The  
458 recovery is, however, within the ranges reported for other MIPs targeting proteins: A MISPE method  
459 targeting the signature peptide NLLGLIEAK (from the SCLC biomarker ProGRP) gave a recovery of  $<25\%$   
460 in precipitated serum [17], and an epitope imprinted on-line MISPE method targeting the sequence  
461 MIQRTPKIQ from beta2-microglobulin showed recoveries of  $\geq 83\%$  in spiked serum samples ( $\mu\text{g mL}^{-1}$   
462 range). An NSE-imprinted electrochemical sensor based assay reported recoveries between

463 approximately 96-100% in 1:100 diluted serum [19]. Most likely, the dilution factor of the latter  
464 method reduces the complexity sufficiently to ensure complete recoveries. Nevertheless, MIP 1 has  
465 excellent compatibility with complex matrices, such as minimally diluted serum, and is therefore likely  
466 to be able to analyse NSE in serum at levels below the clinical reference range. In addition, since the  
467 recovery drops when the MIP is replaced by the NIP when extracting complex samples, then imprinting  
468 is likely to play an essential role in the extraction. The lack of selective binding sites in the NIP leads to  
469 the drop in recovery as ELPLYR must compete with the myriad tryptic peptides in the digested serum  
470 for interaction with the solid-phase.

471 The efficient extraction of ELPLYR for complex matrices using MIP demonstrates the value of MIPs as  
472 potential tools in diagnostics as well as aiding in biomarker validation.

### 473 **3.5 ANALYTICAL EVALUATION IN COMPLEX MATRICES**

474 The analytical performance was evaluated by determining the linearity, LOD, and LOQ of NSE in  
475 digested human serum (n=3). The method is linear in the disease range (3.4–344.2 ng mL<sup>-1</sup>) [21], and  
476 the linear regression was within acceptable limits ( $R^2 > 0.99$ , slope 0.0026, intercept -0.0019). The LOD  
477 and LOQ were estimated to be 1.8 (S/N=3) and 6.0 ng mL<sup>-1</sup> (S/N=10), respectively, which is a very  
478 significant finding because the LOQ is below the median reference levels in humans (8.6 ng mL<sup>-1</sup>) [22].  
479 Therefore, the on-line MISPE method has great potential in NSE analysis and quantification, subject  
480 to efficient digestion of the complex samples. Presently, the digestion efficiency of NSE is  
481 approximately 50%, therefore further improvements in the digestion could yield up to two-fold  
482 reductions in the LOD and LOQ. Furthermore, the use of more contemporary MS systems in  
483 combination with nanoflow LC are expected to reduce the LOD and LOQ yet further. Irrespective of  
484 the further refinements that are possible, the on-line MISPE protocol developed and presented here  
485 can quantify NSE below the reference level in human serum. The good performance of MIPs in contact  
486 with complex matrices demonstrates the potential value MIPs have in diagnostics.

## 487 4.0 Conclusions

488 The present work demonstrates the successful design, synthesis, and exploitation of robust synthetic  
489 receptors targeting the signature peptide of the biomarker NSE for the diagnosis of SCLC. Two MIPs  
490 were synthesized in a convenient beaded format using precipitation polymerisation and packed into  
491 columns for on-line MISPE-LC-MS/MS. Initial optimisation work revealed that the polymers had high  
492 affinity for the target, and further optimisation of the MISPE protocol enabled conditions to be  
493 established where the target could be extracted efficiently from water-rich samples. Thereafter, the  
494 analytical potential of the most promising synthetic receptor (MIP 1) was evaluated with complex  
495 matrices. The on-line extraction method had acceptable recoveries, excellent linearity, and LODs and  
496 LOQs for NSE which were in the low ng mL<sup>-1</sup> range and, very significantly, below the human reference  
497 level in serum (which is 8.6 ng mL<sup>-1</sup>). The low cost and stability of the MIP, combined with the  
498 automated on-line MISPE enrichment and LC-MS/MS of the target molecule, is very promising for SCLC  
499 diagnosis in particular, and the low-cost analysis of analytes in complex matrices in general, as well as  
500 for aiding biomarker validation.

## 501 5.0 Acknowledgements

502 This work was supported by the Horizon 2020 Research Framework Programme of the European  
503 Commission BioCapture project (722171). We thank Dr. R. Trones from G&T Septeck AS, Norway, for  
504 assisting with the packing of the MIPs and NIPs into columns.

## References

- 506 [1] G. Poste, Bring on the biomarkers, *Nature* 469(7329) (2011) 156-157.
- 507 [2] R.M. Lequin, Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA), *Clin. Chem.*
- 508 51(12) (2005) 2415-2418.
- 509 [3] K. Haupt, K. Mosbach, Molecularly imprinted polymers and their use in biomimetic sensors, *Chem.*
- 510 *Rev.* 100(7) (2000) 2495-2504.
- 511 [4] A. Mujahid, N. Iqbal, A. Afzal, Bioimprinting strategies: From soft lithography to biomimetic sensors
- 512 and beyond, *Biotechnol. Adv.* 31(8) (2013) 1435-1447.
- 513 [5] A. Poma, A.P. Turner, S.A. Piletsky, Advances in the manufacture of MIP nanoparticles, *Trends*
- 514 *Biotechnol.* 28(12) (2010) 629-637.
- 515 [6] G. Vasapollo, R.D. Sole, L. Mergola, M.R. Lazzoi, A. Scardino, S. Scorrano, G. Mele, Molecularly
- 516 imprinted polymers: present and future prospective, *Int. J. Mol. Sci.* 12(9) (2011) 5908-5945.
- 517 [7] M.X. Li, X.H. Wang, L.M. Zhang, X.P. Wei, A high sensitive epitope imprinted electrochemical sensor
- 518 for bovine serum albumin based on enzyme amplifying, *Anal. Biochem.* 530 (2017) 68-74.
- 519 [8] J.Z. Hilt, M.E. Byrne, Configurational biomimesis in drug delivery: molecular imprinting of
- 520 biologically significant molecules, *Adv. Drug Delivery Rev.* 56(11) (2004) 1599-620.
- 521 [9] E. Saridakis, S. Khurshid, L. Govada, Q. Phan, D. Hawkins, G.V. Crichlow, E. Lolis, S.M. Reddy, N.E.
- 522 Chayen, Protein crystallization facilitated by molecularly imprinted polymers, *Proc. Natl. Acad. Sci. U.*
- 523 *S. A.* 108(27) (2011) 11081-6.
- 524 [10] L. Chen, X. Wang, W. Lu, X. Wu, J. Li, Molecular imprinting: perspectives and applications, *Chem.*
- 525 *Soc. Rev.* 45(8) (2016) 2137-211.
- 526 [11] W.J. Cheong, S.H. Yang, F. Ali, Molecular imprinted polymers for separation science: a review of
- 527 reviews, *J. Sep. Sci.* 36(3) (2013) 609-628.
- 528 [12] C. Rossetti, M.A. Świtnicka-Plak, T.G. Halvorsen, P.A. Cormack, B. Sellergren, L. Reubsaet,
- 529 Automated Protein Biomarker Analysis: on-line extraction of clinical samples by Molecularly Imprinted
- 530 Polymers, *Sci. Rep.* 7 (2017) 44298.
- 531 [13] A. Rachkov, M. Hu, E. Bulgarevich, T. Matsumoto, N. Minoura, Molecularly imprinted polymers
- 532 prepared in aqueous solution selective for [Sar<sup>1</sup>, Ala<sup>8</sup>] angiotensin II, *Anal. Chim. Acta* 504(1) (2004)
- 533 191-197.
- 534 [14] F. Yang, D. Deng, X. Dong, S. Lin, Preparation of an epitope-imprinted polymer with antibody-like
- 535 selectivity for beta2-microglobulin and application in serum sample analysis with a facile method of
- 536 on-line solid-phase extraction coupling with high performance liquid chromatography, *J. Chromatogr.*
- 537 *A* 1494 (2017) 18-26.
- 538 [15] M. Kempe, K. Mosbach, Separation of amino acids, peptides and proteins on molecularly
- 539 imprinted stationary phases, *J. Chromatogr. A* 691(1-2) (1995) 317-323.
- 540 [16] R. Boysen, Advances in the development of molecularly imprinted polymers for the separation
- 541 and analysis of proteins with liquid chromatography, *J. Sep. Sci.* 42(1) (2019) 51-71.
- 542 [17] C. Rossetti, A. Abdel Qader, T.G. Halvorsen, B.r. Sellergren, L. Reubsaet, Antibody-free biomarker
- 543 determination: Exploring molecularly imprinted polymers for pro-gastrin releasing peptide, *Anal.*
- 544 *Chem.* 86(24) (2014) 12291-12298.
- 545 [18] S.B. Torsetnes, S.G. Løvbak, C. Claus, H. Lund, M.S. Nordlund, E. Paus, T.G. Halvorsen, L. Reubsaet,
- 546 Immunocapture and LC-MS/MS for selective quantification and differentiation of the isozymes of the
- 547 biomarker neuron-specific enolase in serum, *J. Chromatogr. B* 929 (2013) 125-132.
- 548 [19] X. Wang, Y. Wang, X. Ye, T. Wu, H. Deng, P. Wu, C. Li, Sensing platform for neuron specific enolase
- 549 based on molecularly imprinted polymerized ionic liquids in between gold nanoarrays, *Biosens.*
- 550 *Bioelectron.* 99 (2018) 34-39.
- 551 [20] C. Rosting, A. Gjelstad, T.G. Halvorsen, Water-soluble dried blood spot in protein analysis: a proof-
- 552 of-concept study, *Anal. Chem.* 87(15) (2015) 7918-7924.

553 [21] D. Yu, K. Du, T. Liu, G. Chen, Prognostic value of tumor markers, NSE, CA125 and SCC, in operable  
554 NSCLC Patients, *Int. J. Mol. Sci.* 14(6) (2013) 11145-11156.  
555 [22] T. Esscher, L. Steinholtz, J. Bergh, E. Nöu, K. Nilsson, S. Pålman, Neurone specific enolase: a useful  
556 diagnostic serum marker for small cell carcinoma of the lung, *Thorax* 40(2) (1985) 85-90.

557

## 558 Figure captions

559

560 **Figure 1.** (A) The on-line MISPE system. Firstly, the analyte is injected onto the MIP (left). Following  
561 sample loading, the system switches and the analyte is gradient eluted onto a C<sub>18</sub> analytical column  
562 before determination by a triple quadrupole MS (right). (B) Set-up for initial optimization. The MIP  
563 (or NIP) is coupled directly to the MS.

564

565 **Figure 2.** Chemical structures of the NSE signature peptide (A) and the structural analogue of the  
566 NSE signature peptide used as template during MIP syntheses (B).

567

568 **Figure 3.** Retention factors (k) of MIP 1 and NIP 1 at 20  $\mu\text{L min}^{-1}$  isocratic flow with mobile phases  
569 95:5, 96:4 and 97:3 mM FA:MeCN (v/v). \*P $\leq$ 0.05

570

571 **Figure 4.** Recoveries of ELPLYR after spiking 5 ng mL<sup>-1</sup> digested NSE to matrices of increasing  
572 complexity (50 mM ABC containing 50 nM digested BSA, SPE-treated digested human serum, and  
573 untreated digested human serum, n=3).

574

575

576

577

578

579

580

581 Table 1. Recoveries of ELPLYR tryptic peptide using loading (extraction) times of 5, 7.5, 10, 12.5, and  
 582 20 min.

Extraction time (min)	ELPLYR Recovery (%)	RSD (%)
5	95.3	1.4
7.5	103	2.9
10	100	5.0
12.5	105	9.5
20	102	4.4

583

584

585


586 Table 2. Recoveries of seven BSA tryptic peptides loaded for 5, 10, and 20 min (n=3).

Peptide	5 min		10 min		20 min	
	Recovery (%)	RSD (%)	Recovery (%)	RSD (%)	Recovery (%)	RSD (%)
DAELGSFLYEYSR	78.9	37.4	80.3	1.1	73.4	12.4
YICDNQDTISSK	83.9	6.5	88.9	3.8	82.2	9.1
HLVDEPQNLIL	94.7	0.8	86.9	12.3	79.5	3.0
AEFVEVTK	45.0	54.0	19.8	11.6	11.9	114.6
LVTDLTK	9.5	173.2	0	0	0	0
HPEYAVSVLLR	46.1	19.0	41.9	9.2	42.9	11.9
LGEYGFQNALIVR	107.5	14.2	97.0	5.8	95.1	0.1
<b>Average</b>	<b>66.5</b>	<b>39.5</b>	<b>59.3</b>	<b>6.3</b>	<b>51.9</b>	<b>21.6</b>

587

588






589


590 **Figure 1**

591

592



593




594

595

596 **Figure 2**

597


598



599

600 **Figure 3**

601



602

603 **Figure 4**

604

605